Seaport Therapeutics, Inc. Common Stock (NASDAQ:SPTX) — Market Cap & Net Worth
Market Cap & Net Worth: Seaport Therapeutics, Inc. Common Stock (SPTX)
Seaport Therapeutics, Inc. Common Stock (NASDAQ:SPTX) has a market capitalization of $871.78 Million ($871.78 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9704 globally and #2604 in its home market, demonstrating a 10.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seaport Therapeutics, Inc. Common Stock's stock price $17.97 by its total outstanding shares 53027817 (53.03 Million). Review debt load of Seaport Therapeutics, Inc. Common Stock to assess the company's total debt and financial obligations.
Seaport Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Seaport Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $952.91 Million to $952.91 Million (0.00% CAGR).
Seaport Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seaport Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SPTX by Market Capitalization
Companies near Seaport Therapeutics, Inc. Common Stock in the global market cap rankings as of June 17, 2026.
Key companies related to Seaport Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Seaport Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Seaport Therapeutics, Inc. Common Stock's market cap moved from $952.91 Million to $ 952.91 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $952.91 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Seaport Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $871.78 Million USD |
| MoneyControl | $871.78 Million USD |
| MarketWatch | $871.78 Million USD |
| marketcap.company | $871.78 Million USD |
| Reuters | $871.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce l… Read more